Search

everythinglearnresearchcommunity

for

Search:↓

Pyluritamide and RU58841 are compared for effectiveness in addition to dutasteride for hair loss treatment. Reddit users report great results with RU58841, but data suggests pyluritamide may have better affinity.

The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.

The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.

The conversation is about a person starting treatment with RU58841 for hair loss. They are asked to share progress pictures to show if the treatment is effective.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

Researching and developing an effective local antagonist to block the androgen receptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.

A user is considering using RU58841 to treat hair loss and asks if it can be effective for 4-5 years. Some suggest starting with a lower concentration and debate the safety of RU58841 compared to approved drugs like finasteride.

A user is considering whether to continue using RU58841 or switch to hair system patches for a receding hairline, while already using finasteride, oral minoxidil, and microneedling. Another user suggests buying RU58841 in powder form to save money and notes the original poster's hair has significantly improved.

The conversation discusses using RU58841 for hair loss, with OP experiencing thinning in the front area and steady hair loss. OP plans to try microneedling while avoiding finasteride and dutasteride.

The user experienced increased hair shedding after using RU58841 for two months, but found relief from scalp itchiness. Other users shared similar shedding experiences and discussed side effects like joint pain, while also mentioning the use of finasteride and minoxidil.

The user shared progress pictures showing significant improvement in hair loss after using finasteride, RU58841, and undergoing a 3000 graft hair transplant. They plan to get another transplant due to remaining thin areas.

The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.

A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

The user experienced side effects from finasteride and is considering adding Alfatradiol or Fluridil to their regimen, which includes Minoxidil, dermarolling, and ketoconazole. Fluridil is noted to be more effective than Alfatradiol but less effective than finasteride, with mild side effects reported.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The user experienced significant hair loss after using RU58841, a hair loss treatment, and had to undergo a hair transplant to rectify the damage. They're asking others who've used RU58841 about their experiences, particularly if they also experienced shedding, if their hair grew back, when they started using RU, and other related questions.

The user has been managing hair loss with microneedling, Nutrafol, topical finasteride/minoxidil foam, LLLT, and Nizoral, and plans to add oral minoxidil. They are seeing improvement and are cautious about using oral finasteride due to past gynecomastia concerns.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

Green tea extract and soy isoflavones may help with hair loss by inhibiting DHT and providing additional health benefits. Combining these with finasteride and possibly using nizoral shampoo could enhance effectiveness in managing hair loss.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The conversation is about choosing between RU58841 and topical spironolactone for hair loss treatment. The user is currently using a topical solution with minoxidil, alfatradiol, and progesterone, and is concerned about side effects and effectiveness of both RU58841 and spironolactone.